Lung Cancer Translational Research Award
This grant funds advanced translational lung cancer research that moves promising ideas toward clinical use, supporting both late-stage preclinical studies and pilot clinical trials.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 23, 2026: Pre-Application (Preproposal) | September 2, 2026: Full Application | September 4, 2026: End of Application Verification Period
Funding Amounts: ~$9.1M total funding; ~6 awards; up to $1.35M (3 yrs, Level 1) or $1.85M (4 yrs, Level 2) per award (total costs)
Summary: Supports advanced translational research to move promising lung cancer concepts into clinical applications, addressing at least one FY26 LCRP area of emphasis.
Key Information: Pre-application required; open to domestic and foreign organizations; pilot clinical trials allowed (Level 2).
Description
This opportunity, offered by the Dept. of the Army’s USAMRAA through the Congressionally Directed Medical Research Programs (CDMRP), aims to accelerate translational lung cancer research by supporting projects that can move promising ideas into clinical application. The program is open to a broad range of translational studies: advanced/late-stage preclinical work or correlative studies (Funding Level 1), and pilot clinical trials of novel interventions (Funding Level 2). Projects must address at least one of the FY26 Lung Cancer Research Program (LCRP) Areas of Emphasis, which span biology, prevention, detection, treatment, and survivorship.
